These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38702918)

  • 41. Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.
    Lipton RB; Halker Singh RB; Mechtler L; McVige J; Ma J; Yu SY; Stokes J; Dabruzzo B; Gandhi P; Ashina M
    Cephalalgia; 2023 Aug; 51(8):3331024231190296. PubMed ID: 37638400
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
    Schwedt TJ; Lipton RB; Ailani J; Silberstein SD; Tassorelli C; Guo H; Lu K; Dabruzzo B; Miceli R; Severt L; Finnegan M; Trugman JM
    Cephalalgia; 2022 Jan; 42(1):3-11. PubMed ID: 34521260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Physiologically-based pharmacokinetic modeling of quinidine to establish a CYP3A4, P-gp, and CYP2D6 drug-drug-gene interaction network.
    Feick D; Rüdesheim S; Marok FZ; Selzer D; Loer HLH; Teutonico D; Frechen S; van der Lee M; Moes DJAR; Swen JJ; Schwab M; Lehr T
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1143-1156. PubMed ID: 37165978
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
    Gandhi Y; Eley T; Fura A; Li W; Bertz RJ; Garimella T
    Clin Pharmacokinet; 2018 Aug; 57(8):911-928. PubMed ID: 29353349
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
    Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
    J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers.
    Huledal G; Olsson B; Önnestam K; Dalén P; Lindqvist D; Kruse M; Bröijersén A
    Eur J Clin Pharmacol; 2019 Mar; 75(3):313-320. PubMed ID: 30443705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atogepant: First Approval.
    Deeks ED
    Drugs; 2022 Jan; 82(1):65-70. PubMed ID: 34813050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Olkkola KT; Laine K
    Br J Clin Pharmacol; 2010 Jul; 70(1):78-87. PubMed ID: 20642550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib.
    De Buck S; Kucher K; Hara H; Gray C; Woessner R
    Biopharm Drug Dispos; 2018 Sep; 39(8):394-402. PubMed ID: 30171694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
    Brennan BJ; Moreira SA; Morcos PN; Navarro MT; Asthappan J; Goelzer P; Weigl P; Smith PF
    Clin Pharmacokinet; 2013 Sep; 52(9):805-13. PubMed ID: 23712757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
    Tassorelli C; Onishchenko K; Halker Singh RB; Duan M; Dupont-Benjamin L; Hemstock M; Voller C; McAllister P; Nahas SJ; Gandhi P; Ailani J
    Cephalalgia; 2024 Feb; 44(2):3331024241235156. PubMed ID: 38410850
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study.
    Hunt TL; Tzanis E; Bai S; Manley A; Chitra S; McGovern PC
    Eur J Drug Metab Pharmacokinet; 2021 Jan; 46(1):85-92. PubMed ID: 33180250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Drug-Drug Interaction Profile of Presatovir.
    Xin Y; Weng W; Murray BP; Eisenberg EJ; Chien JW; Ling J; Silverman JA
    J Clin Pharmacol; 2018 Jun; 58(6):771-780. PubMed ID: 29412463
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
    Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.